Fortrea Holdings Inc. (FTRE)vsJohnson & Johnson (JNJ)
FTRE
Fortrea Holdings Inc.
$23.14
-10.61%
HEALTHCARE · Cap: $2.14B
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 3611% more annual revenue ($99.33B vs $2.68B). JNJ leads profitability with a 16.2% profit margin vs -3.2%. FTRE appears more attractively valued with a PEG of 0.34. JNJ earns a higher WallStSmart Score of 57/100 (C).
FTRE
Hold41
out of 100
Grade: D
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-39.5%
Fair Value
$8.31
Current Price
$23.14
$14.83 premium
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Areas to Watch
Operating margin of 2.6%
Weak financial health signals
ROE of -85.0% — below average capital efficiency
Revenue declined 4.5%
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : FTRE
The strongest argument for FTRE centers on PEG Ratio. PEG of 0.34 suggests the stock is reasonably priced for its growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bear Case : FTRE
The primary concerns for FTRE are Operating Margin, Piotroski F-Score, Return on Equity. Debt-to-equity of 2.13 is elevated, increasing financial risk.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
FTRE profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
FTRE carries more volatility with a beta of 1.91 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 41/100), backed by strong 16.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fortrea Holdings Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. The company is headquartered in Durham, North Carolina.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?